These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 24706010)

  • 21. White matter integrity determined with diffusion tensor imaging in older adults without dementia: influence of amyloid load and neurodegeneration.
    Kantarci K; Schwarz CG; Reid RI; Przybelski SA; Lesnick TG; Zuk SM; Senjem ML; Gunter JL; Lowe V; Machulda MM; Knopman DS; Petersen RC; Jack CR
    JAMA Neurol; 2014 Dec; 71(12):1547-54. PubMed ID: 25347157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly.
    Koivumäki M; Ekblad L; Lantero-Rodriguez J; Ashton NJ; Karikari TK; Helin S; Parkkola R; Lötjönen J; Zetterberg H; Blennow K; Rinne JO; Snellman A
    Alzheimers Res Ther; 2024 May; 16(1):112. PubMed ID: 38762725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hippocampal subregional volume changes in elders classified using positron emission tomography-based Alzheimer's biomarkers of β-amyloid deposition and neurodegeneration.
    Busatto Filho G; Duran FLS; Squarzoni P; Coutinho AMN; Rosa PGP; Torralbo L; Pachi CGDF; da Costa NA; Porto FHG; Carvalho CL; Brucki SMD; Nitrini R; Forlenza OV; Leite CDC; Buchpiguel CA; de Paula Faria D
    J Neurosci Res; 2021 Feb; 99(2):481-501. PubMed ID: 33073383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of Comorbidity of Cerebrovascular Disease and Amyloid-β on Alzheimer's Disease.
    Yassi N; Hilal S; Xia Y; Lim YY; Watson R; Kuijf H; Fowler C; Yates P; Maruff P; Martins R; Ames D; Chen C; Rowe CC; Villemagne VL; Salvado O; Desmond PM; Masters CL
    J Alzheimers Dis; 2020; 73(3):897-907. PubMed ID: 31884485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diversity of neurodegenerative pathophysiology in nondemented patients with major depressive disorder: Evidence of cerebral amyloidosis and hippocampal atrophy.
    Wu KY; Lin KJ; Chen CH; Chen CS; Liu CY; Huang SY; Yen TC; Hsiao IT
    Brain Behav; 2018 Jul; 8(7):e01016. PubMed ID: 29927088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subthreshold Amyloid Predicts Tau Deposition in Aging.
    Leal SL; Lockhart SN; Maass A; Bell RK; Jagust WJ
    J Neurosci; 2018 May; 38(19):4482-4489. PubMed ID: 29686045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of Plasma Neurofilament Light in the 1Florida Alzheimer's Disease Research Center (ADRC).
    Barker W; Quinonez C; Greig MT; Behar R; Chirinos C; Rodriguez RA; Rosselli M; Rodriguez MJ; Cid RC; Rundek T; McFarland K; Hanson K; Smith G; DeKosky S; Vaillancourt D; Adjouadi M; Marsiske M; Ertekin-Taner N; Golde T; Loewenstein DA; Duara R
    J Alzheimers Dis; 2021; 79(1):59-70. PubMed ID: 33216030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Objective subtle cognitive difficulties predict future amyloid accumulation and neurodegeneration.
    Thomas KR; Bangen KJ; Weigand AJ; Edmonds EC; Wong CG; Cooper S; Delano-Wood L; Bondi MW;
    Neurology; 2020 Jan; 94(4):e397-e406. PubMed ID: 31888974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. β-amyloid, hippocampal atrophy and their relation to longitudinal brain change in cognitively normal individuals.
    Fletcher E; Villeneuve S; Maillard P; Harvey D; Reed B; Jagust W; DeCarli C
    Neurobiol Aging; 2016 Apr; 40():173-180. PubMed ID: 26973117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity.
    Jack CR; Wiste HJ; Weigand SD; Knopman DS; Lowe V; Vemuri P; Mielke MM; Jones DT; Senjem ML; Gunter JL; Gregg BE; Pankratz VS; Petersen RC
    Neurology; 2013 Nov; 81(20):1732-40. PubMed ID: 24132377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community.
    Petersen RC; Wiste HJ; Weigand SD; Rocca WA; Roberts RO; Mielke MM; Lowe VJ; Knopman DS; Pankratz VS; Machulda MM; Geda YE; Jack CR
    JAMA Neurol; 2016 Jan; 73(1):85-92. PubMed ID: 26595683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative Gradient Echo MRI Identifies Dark Matter as a New Imaging Biomarker of Neurodegeneration that Precedes Tisssue Atrophy in Early Alzheimer's Disease.
    Kothapalli SVVN; Benzinger TL; Aschenbrenner AJ; Perrin RJ; Hildebolt CF; Goyal MS; Fagan AM; Raichle ME; Morris JC; Yablonskiy DA
    J Alzheimers Dis; 2022; 85(2):905-924. PubMed ID: 34897083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease.
    Lim YY; Villemagne VL; Laws SM; Ames D; Pietrzak RH; Ellis KA; Harrington KD; Bourgeat P; Salvado O; Darby D; Snyder PJ; Bush AI; Martins RN; Masters CL; Rowe CC; Nathan PJ; Maruff P;
    Neurobiol Aging; 2013 Nov; 34(11):2457-64. PubMed ID: 23769397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Entorhinal Tau Pathology, Episodic Memory Decline, and Neurodegeneration in Aging.
    Maass A; Lockhart SN; Harrison TM; Bell RK; Mellinger T; Swinnerton K; Baker SL; Rabinovici GD; Jagust WJ
    J Neurosci; 2018 Jan; 38(3):530-543. PubMed ID: 29192126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease.
    Jack CR; Knopman DS; Weigand SD; Wiste HJ; Vemuri P; Lowe V; Kantarci K; Gunter JL; Senjem ML; Ivnik RJ; Roberts RO; Rocca WA; Boeve BF; Petersen RC
    Ann Neurol; 2012 Jun; 71(6):765-75. PubMed ID: 22488240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity.
    Costoya-Sánchez A; Moscoso A; Silva-Rodríguez J; Pontecorvo MJ; Devous MD; Aguiar P; Schöll M; Grothe MJ;
    JAMA Neurol; 2023 Oct; 80(10):1051-1061. PubMed ID: 37578787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer's Disease-Modifying Therapy.
    Manjavong M; Kang JM; Diaz A; Ashford MT; Eichenbaum J; Aaronson A; Miller MJ; Mackin S; Tank R; Weiner M; Nosheny R
    J Prev Alzheimers Dis; 2024; 11(5):1198-1205. PubMed ID: 39350364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease.
    Huang SY; Zhang YR; Guo Y; Du J; Ren P; Wu BS; Feng JF; ; Cheng W; Yu JT
    Alzheimers Dement; 2024 May; 20(5):3251-3269. PubMed ID: 38501315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer disease.
    Wang L; Benzinger TL; Hassenstab J; Blazey T; Owen C; Liu J; Fagan AM; Morris JC; Ances BM
    Neurology; 2015 Mar; 84(12):1254-60. PubMed ID: 25716355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis.
    Andrews KA; Frost C; Modat M; Cardoso MJ; ; Rowe CC; Villemagne V; Fox NC; Ourselin S; Schott JM
    Neurobiol Aging; 2016 Mar; 39():99-107. PubMed ID: 26923406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.